Medline resumed with a Buy at Citi
Citi resumed coverage of Medline (MDLN) with a Buy rating and $60 price target following a period of suspension. The company’s Q4 report came in well ahead of expectations on broad-based strength, the analyst tells investors in a research note. Citi believes Medline has a “compelling set-up” into fiscal 2026 as a “safety trade.”
Read More on MDLN:
- Medline price target raised to $53 from $50 at JPMorgan
- Medline price target raised to $60 from $55 at Tigress Financial
- Medline 75M share Secondary priced at $41.00
- Medline announces launch of secondary offering of Class A common stock
- Medline files to sell 75M shares of Class A common stock for holders
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Elon Musk Grok AI Predicts Solana Could Hit $400+ By 2027
Investment in Canada’s mining sector to grow with global demand, BMO
Morgan Stanley Gives Huge Stock Market Crash Warning in 30 Days
Pundit Says This News Is Highly Bullish for Ripple and XRP
Crypto prices
More
